xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

313

Orlandi et al.

variants included septal deviation > concha bullosa >

Symptoms INCS produced greater relief of total and specific

(obstructive) symptoms. No difference in secretory symptoms.

TABLE VIII-5 Evidence for INCS in the management of RARS Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Dolor 421 2001 2 DBRCT 10-day cefuroxime, 3-day xylometazoline, and 1. 21-day INCS 2. 21-day placebo Symptoms; QoL scores (SNOT-20 and SF-12); number of ARS recurrences INCS with xylometazoline and cefuroxime improves clinical success rates and accelerates time to recovery. No significant different in number of ARS recurrences. Meltzer 435 2000 2 DBRCT 21-day amoxicillin clavulanate and 1. 21-day INCS

reduction in facial pain and

sensitivity. No difference in clinical outcomes.

TABLE VIII-4 Evidence for anatomic contributing factors for RARS Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Alkire 341 2010 3 Retrospective case-control 36 patients meeting strict criteria for RARS; 42 control patients Anatomical variants seenonCT Higher presence of infraorbital ethmoid cells and smaller infundibular widths in RARS patients Loftus 207 2016 4 Retrospective case series 26 patients meeting criteria for RARS were evaluated for anatomic variants Anatomical variants seenonCT Anatomic variants in RARS patients was not higher than the general population, but underpowered without control cohort Mohapatra 503 2017 4 Retrospective case series

paradoxical middle turbinate, but no comparison group

Symptoms INCS resulted in greater

Most common anatomic

Anatomical variants seenonCT

Qvarnberg 504 1992 2 DBRCT 7-day erythromycin and 1. 3-month INCS 2. 3-month placebo

2. 21-day placebo

160 patients with history of RARS, but negative scans